Oxidized
cholesterol metabolites (
oxysterols) promote
inflammation in a variety of cell types and are thought to be involved in a number of disease pathologies.
Oxysterol concentrations are increased in pregnancy, together with systemic oxidative stress and
inflammation. We tested the hypothesis that
oxysterols 25-hydroxycholesterol (25-OHC) and
7-ketocholesterol (7-ketoC) promote placental trophoblast
inflammation, and determined the mechanisms involved. Treatment of primary trophoblasts in culture with 25-OHC and 7-ketoC increased the production of proinflammatory
cytokines (
interleukin-6,
macrophage inflammatory protein-1β and tumour
necrosis factor-α) in a concentration-dependent fashion. Inhibition of TLR4 activation using selective inhibitors of TLR4 complex formation (
OxPAPC) or signalling transmission (
CLI095) prevented
lipopolysaccharide (LPS)- and
oxysterol-induced inflammatory
cytokine production. Pretreatment of trophoblasts with selective inhibitors of I-kB
kinase activity (
parthenolide and TPCA-1) reduced
oxysterol- and LPS-stimulated inflammatory responses, consistent with the involvement of the
nuclear factor kappa B (NF-κB) pathway downstream of TLR4 signalling. Both
oxysterols also increased the phosphorylation and nuclear localization of NF-κB subunit p65/RelA.
Oxysterols are also known to activate
liver X receptors (LXRs) which can inhibit inflammatory signalling, either directly or indirectly via membrane
cholesterol reduction. Treatment with the LXR agonist,
T0901317, exerted significant anti-inflammatory effects, reducing LPS- and
oxysterol-driven
cytokine production. Treatment with methyl-β-
cyclodextrin to deplete membrane microdomain
cholesterol and thereby disrupt TLR4 signalling, similarly abrogated their effects. Together, these findings indicate that although
oxysterols likely activate both pro- and anti-inflammatory pathways in the placenta, the predominant effect is the promotion of placental
inflammation via TLR4-dependent activation of NF-κB.